Picture Kentro Design Corporate and Web Design Berlin 650x65px
Document › Details

Abingdon Health Ltd.. (10/16/17). "Press Release: Abingdon Health and Skannex Sign a Co-marketing Agreement".

Organisations Organisation Abingdon Health Ltd.
  Group Abingdon Health (Group)
  Organisation 2 Skannex AS
  Group Skannex (Group)
Products Product lateral flow test
  Product 2 lateral flow system
Persons Person Yates, Chris (Abingdon Health 201710 CEO)
  Person 2 Stabel Olsen, Siri (Skannex 201710 CEO)

Abingdon Health Limited (“Abingdon”), York, UK and Skannex AS, Oslo, Norway (“Skannex”) jointly announce that both parties have entered into a co-marketing agreement to provide lateral flow assay and reader development and manufacturing solutions to contract customers.

Under the agreement, Skannex will be Abingdon Health’s preferred partner for the supply of hand-held reader instrumentation and Abingdon will be Skannex’s preferred partner for lateral flow assay development and manufacturing. Both parties will work collaboratively on providing customers with integrated assay and reader development solutions.

Abingdon’s core expertise lies in the development, manufacturing and commercialisation of rapid lateral flow immunoassay diagnostics and reader systems. The Company provides contract services across all diagnostic sectors including healthcare, veterinary, agri-food, and environmental. In addition to this Abingdon has developed a range of rapid tests in the area of haematology-oncology, the first product Seralite®– FLC was launched in January 2016, and is the world’s first rapid diagnostic device in multiple myeloma.

Skannex Lateral flow reader

Skannex’s core expertise lies in the development, manufacturing and commercialisation of handheld and desktop reader systems for rapid tests. All readers are enabled by Skannex’ proprietary software for image capture and analysis. The flexibility and solidity of the Skannex reader software fulfil the demand from their lateral flow test customers to go to market with a high-quality diagnostic system. The Company has successful customers in all relevant market segments such as Human IVD, Drug of Abuse, Veterinary and Food Toxicity testing.

Commenting on the Agreement:

Chris Yates, CEO of Abingdon Health said:

“We are focused on providing our contract customers with the broadest range of reader instrumentation and Skannex is a clear market leader in the provision of hand-held reader technology. Therefore, we are pleased to be able to offer our contract customers the opportunity to integrate the development of assay and reader solutions that incorporate the skills, technology and experience of both Abingdon Health and Skannex”.

Siri Stabel Olsen, CEO of Skannex said:

“The co-marketing agreement entered into with Abingdon Health is a significant add-on to Skannex customers who seek rapid test development and manufacturing expertise tailored for Skannex reader platforms. With the market moving more and more towards decentralised rapid testing this collaboration will give the marketers and end users the quality and user-friendliness they deserve.”

Abingdon Health Ltd
Phone Number: +44 (0)1904 406082

Skannex AS
Phone Number: +47 99 25 22 74

Record changed: 2017-10-30


Picture [LSUS] – The Business Web Portal 650x65px

More documents for Abingdon Health (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [LSA] – The Business Web Portal 650x89px

» top